{"ticker": {"uuid": "86a31fb0-b9c6-4524-b036-38f4458324ed", "symbol": "AXSM", "name": "Axsome Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Axsome Therapeutics (NASDAQ:AXSM) Upgraded to \"Strong-Buy\" at BMO Capital Markets", "summary": "BMO Capital Markets upgraded Axsome Therapeutics (NASDAQ:AXSM) to a \"strong-buy\" rating, contributing to a consensus \"Moderate Buy\" rating and an average price target of $261.48 among analysts. Despite the company missing Q1 earnings estimates, its revenue increased by 57.4% year", "url": "https://www.marketbeat.com/instant-alerts/axsome-therapeutics-nasdaqaxsm-upgraded-to-strong-buy-at-bmo-capital-markets-2026-07-22/", "source_name": "MarketBeat", "published_at": "2026-07-22T09:41:08", "published_display": "22 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research", "summary": "Zacks Research has downgraded Axsome Therapeutics (NASDAQ:AXSM) from a \"hold\" to a \"strong sell\" rating. This comes despite a broader \"Moderate Buy\" consensus among analysts with a price target of $261.48. The company recently reported mixed quarterly results, with an EPS of -$1.", "url": "https://www.marketbeat.com/instant-alerts/axsome-therapeutics-nasdaqaxsm-rating-lowered-to-strong-sell-at-zacks-research-2026-07-22/", "source_name": "MarketBeat", "published_at": "2026-07-22T09:41:08", "published_display": "22 Jul 2026 09:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "Axsome Therapeutics Inc. (AXSM) has released its Q3 2024 earnings report, showing a beat on both EPS and revenue expectations. The company reported actual EPS of -$1.34 against a consensus of -$1.38, and actual revenue of $104.76 million compared to an expected $98.37 million, ma", "url": "https://www.tipranks.com/stocks/axsm/earnings/q3-2024-report", "source_name": "TipRanks", "published_at": "2026-07-21T17:41:08", "published_display": "21 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target", "summary": "BMO Capital has initiated coverage on Axsome Therapeutics with an Outperform rating and a price target of $310. This follows several recent positive developments for Axsome, including the FDA's acceptance of their New Drug Application for AXS-12 for narcolepsy treatment and the i", "url": "https://www.marketscreener.com/news/bmo-capital-initiates-axsome-therapeutics-at-outperform-with-310-price-target-ce7f51d8d98ef123", "source_name": "marketscreener.com", "published_at": "2026-07-21T11:12:12", "published_display": "21 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fifth Third Bancorp Has $2.74 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM", "summary": "Fifth Third Bancorp significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 554.6% in Q1, now holding 16,214 shares valued at $2.74 million. Despite missing EPS estimates, Axsome Therapeutics' revenue grew by 57.4% year-over-year, and analysts maintain a \"Modera", "url": "https://www.marketbeat.com/instant-alerts/filing-fifth-third-bancorp-has-274-million-stock-holdings-in-axsome-therapeutics-inc-axsm-2026-07-21/", "source_name": "MarketBeat", "published_at": "2026-07-21T08:12:12", "published_display": "21 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics\u2019 Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNN29vc3BEU0NZQnUtenZFNEJhZzRUOGtlbXdDUGtjRk04OEtNbHZFQWNHTS15SVhXNnBNdHRRZmtpRWU1dTRZb1NfVWJHcTZ2Sk9UNEJVNHItd2RVbHZ2NlhGRXl6N1hWV0xweTJuVlNUaHAyYTZaN2JEMmF3bDZ4RUctRmNBa3cydnpzdHR1QllNanRYT0owSmVIMkpsTFhNam1neVFKUFlFeGhCbTJVcFhJZjdjNEROZFptWjA2REp0dw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-20T10:10:18+00:00", "published_display": "20 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of \"Moderate Buy\" from Analysts", "summary": "Axsome Therapeutics (NASDAQ:AXSM) has received a \"Moderate Buy\" consensus rating from 21 analysts, with an average 12-month price target of $259.05. Despite reporting quarterly revenue of $191.2 million, exceeding expectations and up 57.4% year-over-year, the company posted a lar", "url": "https://www.marketbeat.com/instant-alerts/axsome-therapeutics-inc-nasdaqaxsm-receives-average-rating-of-moderate-buy-from-analysts-2026-07-19/", "source_name": "MarketBeat", "published_at": "2026-07-19T06:39:43", "published_display": "19 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics, Inc. $AXSM Stock Holdings Reduced by Principal Financial Group Inc.", "summary": "Principal Financial Group Inc. reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.5% in the first quarter, though it still holds a significant position. Axsome Therapeutics reported mixed quarterly results, beating revenue expectations but missing on earnings per share. ", "url": "https://www.marketbeat.com/instant-alerts/filing-axsome-therapeutics-inc-axsm-stock-holdings-reduced-by-principal-financial-group-inc-2026-07-18/", "source_name": "MarketBeat", "published_at": "2026-07-18T09:12:08", "published_display": "18 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome gains as narcolepsy therapy undergoes FDA review", "summary": "Axsome Therapeutics' stock rose after the FDA accepted its New Drug Application for solriamfetol for narcolepsy, setting a PDUFA date for February 12, 2026. The therapy has shown promise in improving wakefulness and reducing excessive daytime sleepiness in narcolepsy patients. Th", "url": "https://www.msn.com/en-us/health/other/axsome-gains-as-narcolepsy-therapy-undergoes-fda-review/ar-AA27XzwC", "source_name": "MSN", "published_at": "2026-07-18T08:12:08", "published_display": "18 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)", "summary": "Three analysts have issued bullish sentiments on several healthcare companies. Andrew Tsai from Jefferies maintained a Buy rating on Axsome Therapeutics with a $380.00 price target, while Ami Fadia from Needham maintained a Buy rating on Harmony Biosciences Holdings with a $45.00", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AXSM-Q/pressreleases/3337056/analysts-offer-insights-on-healthcare-companies-axsome-therapeutics-axsm-harmony-biosciences-holdings-hrmy-and-adlai-nortye-ltd-sponsored-adr-anl/", "source_name": "The Globe and Mail", "published_at": "2026-07-17T15:12:08", "published_display": "17 Jul 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the AXSM Inflection", "summary": "This article analyzes Axsome Therapeutics Inc. (NASDAQ: AXSM), highlighting weak near-term sentiment but strong long-term potential. It presents three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored for different risk profiles, and details m", "url": "https://news.stocktradersdaily.com/news_release/39/Responsive_Playbooks_and_the_AXSM_Inflection_071726075802_1784289482.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T07:58:00", "published_display": "17 Jul 2026 07:58", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mental Health Stocks Gaining Fresh Attention After Eli Lilly\u2019s Psychedelic Deal", "summary": "Eli Lilly's recent deal involving AtaiBeckley has brought psychedelic and mental health treatments back into focus, prompting investors to re-evaluate companies in this sector. This article highlights three stocks \u2013 Axsome Therapeutics (AXSM), LifeStance Health Group (LFST), and ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/mental-health-stocks-gaining-fresh-attention-after-eli-lilly/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-17T01:39:42", "published_display": "17 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Axsome's AXS-12 Advances to FDA Review for Cataplexy", "summary": "The FDA has accepted Axsome Therapeutics' New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in patients with narcolepsy, setting a PDUFA target action date of May 1, 2027. AXS-12 aims to be a non-scheduled, orally dosed option for daytime use, distinct f", "url": "https://allsci.com/press-release/axsome-advances-first-daytime-oral-therapy-for-cataplexy-in-narcolepsy-toward-fda-decision/", "source_name": "AllSci", "published_at": "2026-07-16T17:39:43", "published_display": "16 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance", "summary": "The FDA has accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a decision expected by May 1, 2027. This potential approval could bolster Axsome's narcolepsy franchise, which already includes Sunosi. However, the", "url": "https://finance.yahoo.com/healthcare/articles/axsomes-nda-axs-12-narcolepsy-155800899.html", "source_name": "Market source", "published_at": "2026-07-16T15:39:42", "published_display": "16 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy Cataplexy", "summary": "Axsome Therapeutics (AXSM) has received FDA acceptance for its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy patients, with a target decision date set and no advisory committee meeting planned. This regulatory milestone provides increased visibili", "url": "https://www.sahmcapital.com/news/content/axsome-therapeutics-axsm-wins-fda-acceptance-for-axs-12-in-narcolepsy-cataplexy-2026-07-16", "source_name": "Sahm", "published_at": "2026-07-16T03:41:19", "published_display": "16 Jul 2026 03:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy", "summary": "Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for treating cataplexy in narcolepsy. The FDA has set a PDUFA target action date of May 1, 2027, and does not currently plan an advisory committee meeting. AXS-12 has Or", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327580/0/en/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-12-for-the-treatment-of-cataplexy-in-narcolepsy.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T03:41:19", "published_display": "16 Jul 2026 03:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome FDA application accepted for 2027 target date", "summary": "Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy. This acceptance sets a formal target action date of May 1, 2027, for the drug, which is designed to address the sudden loss of muscle tone e", "url": "https://grafa.com/en/news/united-states/axsome-therapeutics-fda-accepts-axs-12-nda", "source_name": "grafa.com", "published_at": "2026-07-15T15:33:00", "published_display": "15 Jul 2026 15:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/axsome-therapeutics-wins-us-fda-115214985.html", "source_name": "MT Newswires", "published_at": "2026-07-15T11:52:14+00:00", "published_display": "15 Jul 2026 11:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA currently plans no advisory committee meeting on Axsome's narcolepsy drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOemJvMnowRDMxZmtGcnF6UGtnXzdKeW5zc2hCOEZIR3VkSTJCNWxYS1JUZFRmemhhZ0dlaFdSbzJHdlJUZGJfbWNYMUdHenJ6TFM1WjNza0l1WmJnYXhSTVp2cUdnUDlKWDh3MmVSN0s3MTMwQUo0b3YxWll4a3dkWElBN2s3bjRvSTR2LVZ6eU80c0JNN0hfbkdGb3dOOGdvT2hTY2RPdmZMbVRoal9WNzJCa0xLM0NWRk1DVW51ODk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:00:00+00:00", "published_display": "15 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome gains FDA review for narcolepsy therapy (AXSM:NASDAQ)", "summary": "Axsome Therapeutics' shares rose in premarket trading after the U.S. FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy for narcolepsy. This marks a significant step for the neurology drug developer in bringing its treatment to market.", "url": "https://seekingalpha.com/news/4613956-axsome-gains-fda-review-narcolepsy-therapy", "source_name": "Seeking Alpha", "published_at": "2026-07-15T11:48:12", "published_display": "15 Jul 2026 11:48", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome gets FDA filing acceptance for narcolepsy drug AXS-12", "summary": "Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy patients, setting a target action date of May 1, 2027. The drug, which has Orphan Drug Designation, targets the sudden muscle tone loss ex", "url": "https://www.investing.com/news/company-news/axsome-gets-fda-filing-acceptance-for-narcolepsy-drug-axs12-93CH-4792908", "source_name": "Investing.com", "published_at": "2026-07-15T11:48:12", "published_display": "15 Jul 2026 11:48", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Axsome Therapeutics (NASDAQ: AXSM) AXS-12 narcolepsy NDA", "summary": "Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027, and does not currently plan to ", "url": "https://www.stocktitan.net/sec-filings/AXSM/8-k-axsome-therapeutics-inc-reports-material-event-e07352094022.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:16:53", "published_display": "15 Jul 2026 11:16", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics NDA for AXS-12 accepted by FDA; PDUFA date May 1, 2027", "summary": "The FDA has accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting for this application", "url": "https://www.tradingview.com/news/tradingview:65b21f2ed4b1b:0-axsome-therapeutics-nda-for-axs-12-accepted-by-fda-pdufa-date-may-1-2027/", "source_name": "TradingView", "published_at": "2026-07-15T10:48:12", "published_display": "15 Jul 2026 10:48", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Announces FDA Acceptance of NDA for AXS-12 in Narcolepsy Cataplexy; PDUFA Date Set for May 1, 2027", "summary": "Axsome Therapeutics has announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting for this application. AXS", "url": "https://www.quiverquant.com/news/Axsome+Therapeutics+Announces+FDA+Acceptance+of+NDA+for+AXS-12+in+Narcolepsy+Cataplexy%3B+PDUFA+Date+Set+for+May+1%2C+2027", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T10:48:11", "published_display": "15 Jul 2026 10:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10", "summary": "Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced it will report its second-quarter 2026 financial results on Monday, August 10, 2026, before the opening of the U.S. financial markets. Management will host a conference call at 8", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326700/33090/en/axsome-therapeutics-to-report-second-quarter-2026-financial-results-on-august-10.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T14:40:57", "published_display": "14 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?", "summary": "Axsome Therapeutics has initiated a Phase 3 pediatric ADHD trial (FOCUS-2) for solriamfetol, expanding its strategy to broaden the drug's use across various CNS indications and age groups. This move, alongside an ongoing adolescent program, aims to diversify revenue but also inte", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-14T14:10:32", "published_display": "14 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics to report Q2 2026 results on August 10", "summary": "Axsome Therapeutics will release its financial results for the second quarter of 2026 on Monday, August 10, 2026, before U.S. financial markets open. The company will also host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. A live webcas", "url": "https://scanx.trade/stock-market-news/companies/axsome-therapeutics-to-report-q2-2026-results-on-august-10/45577581", "source_name": "scanx.trade", "published_at": "2026-07-14T12:51:23", "published_display": "14 Jul 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome schedules Aug. 10 call to discuss second-quarter results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPeFVUcWhBRWEwMDFRQjVMNGFKZ2I4TjhkVVQ4akNGLXNET1Z2RTZyTHZxcmpCZGhjMzgtTmNrdEFXWVBBbXYzX2o3U29pZUMzZlFQdi1CZ3V2bFVLZFZvLWttdU9jOGpsZnEyYUp2V2VlRFh5R0hQNDJqV0poYXVrTzhwY3pXUWRRTE9IczBxdWlLX1hFdE11V1dnUnRkeUNTZXM1R1EwU21WT1BrTHFNSkRYQllvOEd5NnFRS2VyWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T11:00:00+00:00", "published_display": "14 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hillsdale Investment Management Inc. Makes New Investment in Axsome Therapeutics, Inc. $AXSM", "summary": "Hillsdale Investment Management Inc. initiated a new position in Axsome Therapeutics (NASDAQ:AXSM) by purchasing 53,363 shares valued at approximately $9.0 million. This comes as institutional and hedge fund ownership in Axsome Therapeutics remains high at 81.49%, with several ma", "url": "https://www.marketbeat.com/instant-alerts/filing-hillsdale-investment-management-inc-makes-new-investment-in-axsome-therapeutics-inc-axsm-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T11:43:23", "published_display": "14 Jul 2026 11:43", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Investors Eye Potential 18.29% Upside In CNS Drug Innovator", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPX0RlSHhzeGJ3ZWdJd0xZaUlZVUlSakp6aHl0VHZsU0hWUXNrWDQyWFJlYVl2Z3dNMDdkenF5bEJ2ZGVmUzJCZnpaZHRXenM3aVh5dXFRbmZpU21HelpTZkNpZWsxYjBUWUhkdkwxanlJdUF1TXlhTFZ5M0hrbGlsTHlseEpVODBiRGhETjFKR2lQZnBDcVcta3VCR3RQWjd2ZDd0b1ZWMld3S19VYUFnWjdMMGFoU1FrQWpybkxla2RTUEJkTVYybndpZEFJZWVTa0JiVjZGa3pHcVpoUno1OW9ENHIybWt2?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:30+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Axsome Therapeutics (AXSM) Stock Is Down Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPM0ZjUDV0UUlhZDJrTXJxc2otc0Rqd1hubklqSTN2MUNfUW5FZ0ZtMkJSMUJab1FzSl9ieUlYRUhYZ0RPSDZ6QXI3em1EVlpSaU5WZGhwRjRTZ1M2ZGt0ZUR1ZktNZFdka2I4SUpWX3RjcF85LTluNzJFc2RyeE9sZkw3OEhuMXowbXdXSmI5N0Q?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T18:37:00+00:00", "published_display": "10 Jul 2026 18:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Axsome Therapeutics (AXSM) Advancing Solriamfetol Into Phase 3 Pediatric ADHD Trials", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/investors-may-respond-axsome-therapeutics-211420306.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T21:14:20+00:00", "published_display": "09 Jul 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Could Be 11% Undervalued Following Its Pediatric ADHD Trial Start", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNY3RZcEdHMnJyeUxQcmFMNlhyNUpMaWZwM2k1T3JJbExVTklfSjl2WWZiN0c4VjNoMFJrdC10b3d3cTdIWnlJYll2MzhlTGh0d3JPNUN5SVFzajRPN1NpeGFPbmxfRHdSd2ZsSGwzOWhnQXU3c1RzQ2lRdkpmTFoySGFIV2JTZS1tbS1oU2I3UEIySE5MSnFzb3JOS1c1UE9taGgtTnVhZkY4LWh3QUZzQWxpT3B6QWtjem5nLTJBS0RwZFVXUkstbXNCVGZubVY3QWJPeXNRQnVsbThEc3RLMVJ5SHYtTllB0gHuAUFVX3lxTE1HMWR4ZG5mdzdkOGM2cmxfa3pfX3g3b05uVWJnS1hTQjdCU2NieE5Cb1FHQUxpM281TjU2bHlESngyY1U4TVlOTzhZRThLMVZWZUdzWVpuTURoLXdkdFdhU2lpZnZ3MkMxUGFWRVhVaW0wTk5ZMjdEOU14R2pUZFpjcTdRLWowMVhhbDh3dk5Pd2hRemxwaFR1UVFndUhTVktoV0xtMWU3Rm41OHhWTTB0aFNrMDVCdC1XeGYwT2xtRkpUaWhROGR4c3dTcUFWc1A3Y3ZPWWMtS3RidlpMR0VPdWJNTmpReWVWVzNHUFE?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T07:58:47+00:00", "published_display": "09 Jul 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Stock Looks Pricey On Sales Yet Fair On Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOaE05S2lvZlowNDhTTnh3N2Y4clo1SURTbDV2dTYwZVMwV3QyVzE2TXZCSkEwMkJja3lZLWVkNkVrVlh1TV9mZkdnU2h1Zlc0LW1xdGM4RUlseHhuZlJwRVgwRm50UXBTdk15eGF2OUhwQThnZ2gwM3ViQzJRNXZHamF5Y0ZPckNyMEltVnVyelVqdHJhSVg4RkgxNmhmdWRKS3FN?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Axsome Therapeutics, Inc. (AXSM) Among the Best Under-the-Radar Stocks to Invest In?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQUnpqNi1fRGdjWlhRSGdodnVGaVVuMExadDlMelpQT0d6MjhyNnJrYUNOOWlxUDh6Tmg3ckhrS0dZYjQzcDNjNExEeldzbG9iVDZOMERGQXVMNmlMdmhTaEFhUVpHUmdMVUMyUzFMSTNNQTUyV0RrQVVwWFF3X2hFWG1RM21pRkNONE1HVU9oMi0xellhY2l4bWw0d3ZSb3NO?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Rallied On Growth Hopes, Is The Upside Already Priced In?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T00:22:54+00:00", "published_display": "29 Jun 2026 00:22", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome starts 468-patient ADHD trial for teens", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPNGNwdDlXR3MyN0VrT1JQUkhJMTBnNEZqbVUtSEptbDJPSkNXM1R3ZVR0VklVMTEwS21QNEEwa2YtUmpmS1FRV1NhR0FzLUhlNlQtNjJYeHFSNmFrakZyazlZWTAwT2JKZVhmcjdkV1JpYmZIXzhuRXlHRU1yWDBsZWZoTk5GLXU4TTZGVHd6YnVYUE0xRjVZUmZsRkJ6VklGUjdncHZ4WHVtY2FsSXgwUUlKR3Bycjl0d0Vmcm9RUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen raises Axsome Therapeutics price target on Auvelity growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNWENxbF92c0N6cjNVZUhwT0FVLUxtNkpSSWs2ei1mM0JwNDk1SGc3b0ZXRDhBeHZjR0hkWHZqREpiSlluMkp6czNYdlMyVkdsQ1lQVlV0WXp1VWVxS09HaGFKVEM0c29TenlocTlNNWFLMGdyelJEQm1qSmJ4SHZ3Z0UyMGhIYTE1QWwtT2RmQS1USkJqUU5sM2RqV0xFbFMwT3IxRjJySk51X0haNTBIcVdiNldabThVbTVlNFJkNldNTFdiN3c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New narcolepsy and sleepiness findings from Axsome at SLEEP 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd2k3Q3VSZGpIRTY1S3BHUXo1eUVDVE9rcVNLVlo0RzJCV2QtYVlaa2tmSUMwUGFTeU5abXFoMU4tejl5Q2ttXzBBNjBCQjBlLXdKeWxkZWFGLVBNZFM1cFJxSjJOcDNQUmtQdThoNWFCNHBrTDdGLV82ODNyYXNmVk9ZMF94QjRqVlpQTTdTVVFfM0I1Smx1Z1RMRHZEaVVUOTk5cnk2T2oyX094QV9VWHcyNWZnc0NJWVRtaQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Herriot Tabuteau sells $11.97m in Axsome stock June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNMTZTNEZpZDJvUmF1d0lWVTZVdnY4Uk9wZnZUejZieWdtLW1HWWJHcS1XWkV0bl9MNUdvT0EzVmNnVWdZQno1WVR2SEpuR3UzWTROVDlQOFY2bG1LU3NDY1RjOF9yeE5UcUVSSGlYdktITTd6T2prUF9qOWNub0JIZEpsYURXdC1WUTVRWVVlNEx5VkZkVlpDSzFGM1NscU5PZ3BwaFhfV2ZtTnViRV9UdEpNTkFMWXRRRXBacUIxWXIwWXRsd2IwUGVwT2F4bHlZS3BLYTlrS3VnQ2hWQmN5bFllZkttQQ?oc=5", "source_name": "Billionaires.Africa", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics stock hits all-time high at 242.5 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxON2pSVXJBOFdmNWQ2SVdMWG15UGFqbnJCUzh5YTRmTEJ2YjhjQ3NpU1FyR3FWc055b2QyTUdzQ3EzR0ZQVzJmU2dJVGE3VUVPc1JaOFhhb3NCYVYzZ200T3h0U0JQQ0tMU1p2ZVF5Z1FyZ2lMMnpZbzYyMFU4X0UtY2QyWFdxdmdXS1p5NHJZbU5jVUxZaDRIRGsyb1Vlcl9rVUttWEFETGpjQ0dpbnNsbE9n?oc=5", "source_name": "Investing.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Axsome Therapeutics (AXSM) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQbkpBYTBMT2I5TDYtd2FUbXJxQ2RnN0N0RUR2NmxvWWpmWFdGWDRxd2xKbDNzY0FocEt1UXhtZFZDQjQ0bDJmYmR4VGRIaEh2VzF4YVp1UGRSOHY2c0NfTnVfdzRmZzQ2UnZCdFFDQ0RUMkdTSmtCajBLMmlxMC1OaUxEN0lMUy1QaDFCX1lFN1p3MGZGMlhqeUtza2RnUzYtVUVsRFNjV21RdlVCV0E?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics, Inc. (NASDAQ:AXSM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$270", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Stock Gains Despite Q1 Loss Exceeding Analyst Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNTmN5OXJXNjh4RHFzZWZZam9OalB2OGxIdDdPblhpSThVMXhUd2NIYU9BRVkyYXNEQWFUT0dhamtkSnBzN1ZubU5jYTNwUHdLS21pcGhSV3VadWVqYk5lT0tpYTQ5MURHdGdyOXBBakw2YXhIblM0TGlsWGp1UVJEdWxRMmZKSUZZMi1mNEdoQkJhMFFvTjRJZWdMVlduTTZJOXp0bWlmOFZfYmZTNmc?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Q1 Loss Widening To US$64.5 Million Tests Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Will Axsome Therapeutics Stock React To Its Upcoming Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPQ3hSZHA1UHBHUmVMSS13UzY2cHZqbmdUYjE5NTh4M01Ma0xFcVpvRWtFUHpWa1QxRE1VQUpYU0l5enNWVnVpb3BxWk9va1RiMEE5VFVjM1hzYkVmdzc5QUpXUG94OFdFUmVXNWdSU1VHY0ZUZzQxQkxYeFdLa04wRGtzSVZIZWV0MEJZRXcwWURYWWhibWoyeFRqY2JxUXBZa2ZjUkxMRkFaMTE1UGxETGNTX2hwaV8wcWtJVXh4TUlTdFJv?oc=5", "source_name": "Trefis", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Axsome Therapeutics (AXSM) Still Attractively Priced After Its 72% One-Year Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQOHgtMHluM0NFTHgtUV9seF9pQ3hKaEtnRDdjS0wxNzR4SDU2Wlg2aVF1bGx2Y0ZWWS1Ma1Y4cHphQjFiMU5qdU1SdElTcGdpSF83ako5cFFRQV9KaWF4aHFTZWk2U090ZmlCR1Z2ZHQtd3FHUllXaWlxWnFpMWYyNmN4OWs0eW1BeW5mOE9pOG9neVlEenJtWEZXQTVpV2JaWFlTekRVQWZ3MGJL?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome sets May 4 earnings release, 8 a.m. call for investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQUUF3YTZKRXBSVFF1LTRJWEQ5NG9mN01Ock96M3ZpQTFTRVI2T2NEQXM2MTFMZWRwMjJZc2UtVFE0VFFCdTJkbEVYcWpLZDR0TlNLLUNJTndPdUxyLTFRLVlBR0ZydTh2eU5SZ0hjdkZqNDZMdTd6Sk5BRkpyUzVQclc0UjhzTEw3a0JvWXM4b0FwVVhnX0pBMl9ESElJLWczY3RxNjkzZzh2RTlNcGZrZ21xMmU1Rm9fYmE0OFRn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPU2M0N3UzU25NdVYxNm12TFVGZjRmVkNSRXEycUlTcnF5c3paa190SGxrVWhrOEpRZ2lqcVFJLWd6R21GWkJCbDl4SGVfOVBSbXNkdlMyckh1R3N5N1hEVldBNnpZaFFYMnlWeWJWdkNaNGpNV0Y4R3dZVnhSSnJVWTRmbHNQUkZxX01keEhBZ2FNUGszR1pjMUItTWZJTWhWeUZPY0ozc18?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What's Driving Axsome Therapeutics' Recent Bull Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPTVEwc2hoc2VncjhFY05TcUx3c2s0SHJpSWoxUEJacHU1T0FoVWw4MkVYdlViaXFTeWxQeU1CRlM3Y1VVWWhVaDAtaEhGUkYtVkFNVGd1V1BaeHl0YXJHZ05GNWp3eE5nWjdlNjFWNTBFbzlLZ2U0OGNuN2dpcTVoRHJtcHNobV9QYmZ5RnFn?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-15T18:15:15+00:00", "published_display": "15 Feb 2026 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Axsome Therapeutics (NASDAQ:AXSM) Upgraded to \"Strong-Buy\" at BMO Capital Markets", "summary": "BMO Capital Markets upgraded Axsome Therapeutics (NASDAQ:AXSM) to a \"strong-buy\" rating, contributing to a consensus \"Moderate Buy\" rating and an average price target of $261.48 among analysts. Despite the company missing Q1 earnings estimates, its revenue increased by 57.4% year", "url": "https://www.marketbeat.com/instant-alerts/axsome-therapeutics-nasdaqaxsm-upgraded-to-strong-buy-at-bmo-capital-markets-2026-07-22/", "source_name": "MarketBeat", "published_at": "2026-07-22T09:41:08", "published_display": "22 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research", "summary": "Zacks Research has downgraded Axsome Therapeutics (NASDAQ:AXSM) from a \"hold\" to a \"strong sell\" rating. This comes despite a broader \"Moderate Buy\" consensus among analysts with a price target of $261.48. The company recently reported mixed quarterly results, with an EPS of -$1.", "url": "https://www.marketbeat.com/instant-alerts/axsome-therapeutics-nasdaqaxsm-rating-lowered-to-strong-sell-at-zacks-research-2026-07-22/", "source_name": "MarketBeat", "published_at": "2026-07-22T09:41:08", "published_display": "22 Jul 2026 09:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "Axsome Therapeutics Inc. (AXSM) has released its Q3 2024 earnings report, showing a beat on both EPS and revenue expectations. The company reported actual EPS of -$1.34 against a consensus of -$1.38, and actual revenue of $104.76 million compared to an expected $98.37 million, ma", "url": "https://www.tipranks.com/stocks/axsm/earnings/q3-2024-report", "source_name": "TipRanks", "published_at": "2026-07-21T17:41:08", "published_display": "21 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target", "summary": "BMO Capital has initiated coverage on Axsome Therapeutics with an Outperform rating and a price target of $310. This follows several recent positive developments for Axsome, including the FDA's acceptance of their New Drug Application for AXS-12 for narcolepsy treatment and the i", "url": "https://www.marketscreener.com/news/bmo-capital-initiates-axsome-therapeutics-at-outperform-with-310-price-target-ce7f51d8d98ef123", "source_name": "marketscreener.com", "published_at": "2026-07-21T11:12:12", "published_display": "21 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fifth Third Bancorp Has $2.74 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM", "summary": "Fifth Third Bancorp significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 554.6% in Q1, now holding 16,214 shares valued at $2.74 million. Despite missing EPS estimates, Axsome Therapeutics' revenue grew by 57.4% year-over-year, and analysts maintain a \"Modera", "url": "https://www.marketbeat.com/instant-alerts/filing-fifth-third-bancorp-has-274-million-stock-holdings-in-axsome-therapeutics-inc-axsm-2026-07-21/", "source_name": "MarketBeat", "published_at": "2026-07-21T08:12:12", "published_display": "21 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics\u2019 Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNN29vc3BEU0NZQnUtenZFNEJhZzRUOGtlbXdDUGtjRk04OEtNbHZFQWNHTS15SVhXNnBNdHRRZmtpRWU1dTRZb1NfVWJHcTZ2Sk9UNEJVNHItd2RVbHZ2NlhGRXl6N1hWV0xweTJuVlNUaHAyYTZaN2JEMmF3bDZ4RUctRmNBa3cydnpzdHR1QllNanRYT0owSmVIMkpsTFhNam1neVFKUFlFeGhCbTJVcFhJZjdjNEROZFptWjA2REp0dw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-20T10:10:18+00:00", "published_display": "20 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of \"Moderate Buy\" from Analysts", "summary": "Axsome Therapeutics (NASDAQ:AXSM) has received a \"Moderate Buy\" consensus rating from 21 analysts, with an average 12-month price target of $259.05. Despite reporting quarterly revenue of $191.2 million, exceeding expectations and up 57.4% year-over-year, the company posted a lar", "url": "https://www.marketbeat.com/instant-alerts/axsome-therapeutics-inc-nasdaqaxsm-receives-average-rating-of-moderate-buy-from-analysts-2026-07-19/", "source_name": "MarketBeat", "published_at": "2026-07-19T06:39:43", "published_display": "19 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics, Inc. $AXSM Stock Holdings Reduced by Principal Financial Group Inc.", "summary": "Principal Financial Group Inc. reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.5% in the first quarter, though it still holds a significant position. Axsome Therapeutics reported mixed quarterly results, beating revenue expectations but missing on earnings per share. ", "url": "https://www.marketbeat.com/instant-alerts/filing-axsome-therapeutics-inc-axsm-stock-holdings-reduced-by-principal-financial-group-inc-2026-07-18/", "source_name": "MarketBeat", "published_at": "2026-07-18T09:12:08", "published_display": "18 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome gains as narcolepsy therapy undergoes FDA review", "summary": "Axsome Therapeutics' stock rose after the FDA accepted its New Drug Application for solriamfetol for narcolepsy, setting a PDUFA date for February 12, 2026. The therapy has shown promise in improving wakefulness and reducing excessive daytime sleepiness in narcolepsy patients. Th", "url": "https://www.msn.com/en-us/health/other/axsome-gains-as-narcolepsy-therapy-undergoes-fda-review/ar-AA27XzwC", "source_name": "MSN", "published_at": "2026-07-18T08:12:08", "published_display": "18 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)", "summary": "Three analysts have issued bullish sentiments on several healthcare companies. Andrew Tsai from Jefferies maintained a Buy rating on Axsome Therapeutics with a $380.00 price target, while Ami Fadia from Needham maintained a Buy rating on Harmony Biosciences Holdings with a $45.00", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AXSM-Q/pressreleases/3337056/analysts-offer-insights-on-healthcare-companies-axsome-therapeutics-axsm-harmony-biosciences-holdings-hrmy-and-adlai-nortye-ltd-sponsored-adr-anl/", "source_name": "The Globe and Mail", "published_at": "2026-07-17T15:12:08", "published_display": "17 Jul 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the AXSM Inflection", "summary": "This article analyzes Axsome Therapeutics Inc. (NASDAQ: AXSM), highlighting weak near-term sentiment but strong long-term potential. It presents three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored for different risk profiles, and details m", "url": "https://news.stocktradersdaily.com/news_release/39/Responsive_Playbooks_and_the_AXSM_Inflection_071726075802_1784289482.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T07:58:00", "published_display": "17 Jul 2026 07:58", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mental Health Stocks Gaining Fresh Attention After Eli Lilly\u2019s Psychedelic Deal", "summary": "Eli Lilly's recent deal involving AtaiBeckley has brought psychedelic and mental health treatments back into focus, prompting investors to re-evaluate companies in this sector. This article highlights three stocks \u2013 Axsome Therapeutics (AXSM), LifeStance Health Group (LFST), and ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/mental-health-stocks-gaining-fresh-attention-after-eli-lilly/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-17T01:39:42", "published_display": "17 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome's AXS-12 Advances to FDA Review for Cataplexy", "summary": "The FDA has accepted Axsome Therapeutics' New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in patients with narcolepsy, setting a PDUFA target action date of May 1, 2027. AXS-12 aims to be a non-scheduled, orally dosed option for daytime use, distinct f", "url": "https://allsci.com/press-release/axsome-advances-first-daytime-oral-therapy-for-cataplexy-in-narcolepsy-toward-fda-decision/", "source_name": "AllSci", "published_at": "2026-07-16T17:39:43", "published_display": "16 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance", "summary": "The FDA has accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a decision expected by May 1, 2027. This potential approval could bolster Axsome's narcolepsy franchise, which already includes Sunosi. However, the", "url": "https://finance.yahoo.com/healthcare/articles/axsomes-nda-axs-12-narcolepsy-155800899.html", "source_name": "Market source", "published_at": "2026-07-16T15:39:42", "published_display": "16 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy Cataplexy", "summary": "Axsome Therapeutics (AXSM) has received FDA acceptance for its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy patients, with a target decision date set and no advisory committee meeting planned. This regulatory milestone provides increased visibili", "url": "https://www.sahmcapital.com/news/content/axsome-therapeutics-axsm-wins-fda-acceptance-for-axs-12-in-narcolepsy-cataplexy-2026-07-16", "source_name": "Sahm", "published_at": "2026-07-16T03:41:19", "published_display": "16 Jul 2026 03:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy", "summary": "Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for treating cataplexy in narcolepsy. The FDA has set a PDUFA target action date of May 1, 2027, and does not currently plan an advisory committee meeting. AXS-12 has Or", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327580/0/en/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-12-for-the-treatment-of-cataplexy-in-narcolepsy.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T03:41:19", "published_display": "16 Jul 2026 03:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome FDA application accepted for 2027 target date", "summary": "Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy. This acceptance sets a formal target action date of May 1, 2027, for the drug, which is designed to address the sudden loss of muscle tone e", "url": "https://grafa.com/en/news/united-states/axsome-therapeutics-fda-accepts-axs-12-nda", "source_name": "grafa.com", "published_at": "2026-07-15T15:33:00", "published_display": "15 Jul 2026 15:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/axsome-therapeutics-wins-us-fda-115214985.html", "source_name": "MT Newswires", "published_at": "2026-07-15T11:52:14+00:00", "published_display": "15 Jul 2026 11:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA currently plans no advisory committee meeting on Axsome's narcolepsy drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOemJvMnowRDMxZmtGcnF6UGtnXzdKeW5zc2hCOEZIR3VkSTJCNWxYS1JUZFRmemhhZ0dlaFdSbzJHdlJUZGJfbWNYMUdHenJ6TFM1WjNza0l1WmJnYXhSTVp2cUdnUDlKWDh3MmVSN0s3MTMwQUo0b3YxWll4a3dkWElBN2s3bjRvSTR2LVZ6eU80c0JNN0hfbkdGb3dOOGdvT2hTY2RPdmZMbVRoal9WNzJCa0xLM0NWRk1DVW51ODk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:00:00+00:00", "published_display": "15 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome gains FDA review for narcolepsy therapy (AXSM:NASDAQ)", "summary": "Axsome Therapeutics' shares rose in premarket trading after the U.S. FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy for narcolepsy. This marks a significant step for the neurology drug developer in bringing its treatment to market.", "url": "https://seekingalpha.com/news/4613956-axsome-gains-fda-review-narcolepsy-therapy", "source_name": "Seeking Alpha", "published_at": "2026-07-15T11:48:12", "published_display": "15 Jul 2026 11:48", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome gets FDA filing acceptance for narcolepsy drug AXS-12", "summary": "Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy patients, setting a target action date of May 1, 2027. The drug, which has Orphan Drug Designation, targets the sudden muscle tone loss ex", "url": "https://www.investing.com/news/company-news/axsome-gets-fda-filing-acceptance-for-narcolepsy-drug-axs12-93CH-4792908", "source_name": "Investing.com", "published_at": "2026-07-15T11:48:12", "published_display": "15 Jul 2026 11:48", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Axsome Therapeutics (NASDAQ: AXSM) AXS-12 narcolepsy NDA", "summary": "Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027, and does not currently plan to ", "url": "https://www.stocktitan.net/sec-filings/AXSM/8-k-axsome-therapeutics-inc-reports-material-event-e07352094022.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:16:53", "published_display": "15 Jul 2026 11:16", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics NDA for AXS-12 accepted by FDA; PDUFA date May 1, 2027", "summary": "The FDA has accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting for this application", "url": "https://www.tradingview.com/news/tradingview:65b21f2ed4b1b:0-axsome-therapeutics-nda-for-axs-12-accepted-by-fda-pdufa-date-may-1-2027/", "source_name": "TradingView", "published_at": "2026-07-15T10:48:12", "published_display": "15 Jul 2026 10:48", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Announces FDA Acceptance of NDA for AXS-12 in Narcolepsy Cataplexy; PDUFA Date Set for May 1, 2027", "summary": "Axsome Therapeutics has announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting for this application. AXS", "url": "https://www.quiverquant.com/news/Axsome+Therapeutics+Announces+FDA+Acceptance+of+NDA+for+AXS-12+in+Narcolepsy+Cataplexy%3B+PDUFA+Date+Set+for+May+1%2C+2027", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T10:48:11", "published_display": "15 Jul 2026 10:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10", "summary": "Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced it will report its second-quarter 2026 financial results on Monday, August 10, 2026, before the opening of the U.S. financial markets. Management will host a conference call at 8", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326700/33090/en/axsome-therapeutics-to-report-second-quarter-2026-financial-results-on-august-10.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T14:40:57", "published_display": "14 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?", "summary": "Axsome Therapeutics has initiated a Phase 3 pediatric ADHD trial (FOCUS-2) for solriamfetol, expanding its strategy to broaden the drug's use across various CNS indications and age groups. This move, alongside an ongoing adolescent program, aims to diversify revenue but also inte", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/is-axsome-therapeutics-axsm-reframing-its-cns-strategy-with/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-14T14:10:32", "published_display": "14 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics to report Q2 2026 results on August 10", "summary": "Axsome Therapeutics will release its financial results for the second quarter of 2026 on Monday, August 10, 2026, before U.S. financial markets open. The company will also host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. A live webcas", "url": "https://scanx.trade/stock-market-news/companies/axsome-therapeutics-to-report-q2-2026-results-on-august-10/45577581", "source_name": "scanx.trade", "published_at": "2026-07-14T12:51:23", "published_display": "14 Jul 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome schedules Aug. 10 call to discuss second-quarter results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPeFVUcWhBRWEwMDFRQjVMNGFKZ2I4TjhkVVQ4akNGLXNET1Z2RTZyTHZxcmpCZGhjMzgtTmNrdEFXWVBBbXYzX2o3U29pZUMzZlFQdi1CZ3V2bFVLZFZvLWttdU9jOGpsZnEyYUp2V2VlRFh5R0hQNDJqV0poYXVrTzhwY3pXUWRRTE9IczBxdWlLX1hFdE11V1dnUnRkeUNTZXM1R1EwU21WT1BrTHFNSkRYQllvOEd5NnFRS2VyWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T11:00:00+00:00", "published_display": "14 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hillsdale Investment Management Inc. Makes New Investment in Axsome Therapeutics, Inc. $AXSM", "summary": "Hillsdale Investment Management Inc. initiated a new position in Axsome Therapeutics (NASDAQ:AXSM) by purchasing 53,363 shares valued at approximately $9.0 million. This comes as institutional and hedge fund ownership in Axsome Therapeutics remains high at 81.49%, with several ma", "url": "https://www.marketbeat.com/instant-alerts/filing-hillsdale-investment-management-inc-makes-new-investment-in-axsome-therapeutics-inc-axsm-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T11:43:23", "published_display": "14 Jul 2026 11:43", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Investors Eye Potential 18.29% Upside In CNS Drug Innovator", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPX0RlSHhzeGJ3ZWdJd0xZaUlZVUlSakp6aHl0VHZsU0hWUXNrWDQyWFJlYVl2Z3dNMDdkenF5bEJ2ZGVmUzJCZnpaZHRXenM3aVh5dXFRbmZpU21HelpTZkNpZWsxYjBUWUhkdkwxanlJdUF1TXlhTFZ5M0hrbGlsTHlseEpVODBiRGhETjFKR2lQZnBDcVcta3VCR3RQWjd2ZDd0b1ZWMld3S19VYUFnWjdMMGFoU1FrQWpybkxla2RTUEJkTVYybndpZEFJZWVTa0JiVjZGa3pHcVpoUno1OW9ENHIybWt2?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:30+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Axsome Therapeutics (AXSM) Stock Is Down Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPM0ZjUDV0UUlhZDJrTXJxc2otc0Rqd1hubklqSTN2MUNfUW5FZ0ZtMkJSMUJab1FzSl9ieUlYRUhYZ0RPSDZ6QXI3em1EVlpSaU5WZGhwRjRTZ1M2ZGt0ZUR1ZktNZFdka2I4SUpWX3RjcF85LTluNzJFc2RyeE9sZkw3OEhuMXowbXdXSmI5N0Q?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T18:37:00+00:00", "published_display": "10 Jul 2026 18:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Axsome Therapeutics (AXSM) Advancing Solriamfetol Into Phase 3 Pediatric ADHD Trials", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/investors-may-respond-axsome-therapeutics-211420306.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T21:14:20+00:00", "published_display": "09 Jul 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Could Be 11% Undervalued Following Its Pediatric ADHD Trial Start", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T07:58:47+00:00", "published_display": "09 Jul 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Stock Looks Pricey On Sales Yet Fair On Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOaE05S2lvZlowNDhTTnh3N2Y4clo1SURTbDV2dTYwZVMwV3QyVzE2TXZCSkEwMkJja3lZLWVkNkVrVlh1TV9mZkdnU2h1Zlc0LW1xdGM4RUlseHhuZlJwRVgwRm50UXBTdk15eGF2OUhwQThnZ2gwM3ViQzJRNXZHamF5Y0ZPckNyMEltVnVyelVqdHJhSVg4RkgxNmhmdWRKS3FN?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Axsome Therapeutics, Inc. (AXSM) Among the Best Under-the-Radar Stocks to Invest In?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQUnpqNi1fRGdjWlhRSGdodnVGaVVuMExadDlMelpQT0d6MjhyNnJrYUNOOWlxUDh6Tmg3ckhrS0dZYjQzcDNjNExEeldzbG9iVDZOMERGQXVMNmlMdmhTaEFhUVpHUmdMVUMyUzFMSTNNQTUyV0RrQVVwWFF3X2hFWG1RM21pRkNONE1HVU9oMi0xellhY2l4bWw0d3ZSb3NO?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Rallied On Growth Hopes, Is The Upside Already Priced In?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T00:22:54+00:00", "published_display": "29 Jun 2026 00:22", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome starts 468-patient ADHD trial for teens", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPNGNwdDlXR3MyN0VrT1JQUkhJMTBnNEZqbVUtSEptbDJPSkNXM1R3ZVR0VklVMTEwS21QNEEwa2YtUmpmS1FRV1NhR0FzLUhlNlQtNjJYeHFSNmFrakZyazlZWTAwT2JKZVhmcjdkV1JpYmZIXzhuRXlHRU1yWDBsZWZoTk5GLXU4TTZGVHd6YnVYUE0xRjVZUmZsRkJ6VklGUjdncHZ4WHVtY2FsSXgwUUlKR3Bycjl0d0Vmcm9RUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen raises Axsome Therapeutics price target on Auvelity growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNWENxbF92c0N6cjNVZUhwT0FVLUxtNkpSSWs2ei1mM0JwNDk1SGc3b0ZXRDhBeHZjR0hkWHZqREpiSlluMkp6czNYdlMyVkdsQ1lQVlV0WXp1VWVxS09HaGFKVEM0c29TenlocTlNNWFLMGdyelJEQm1qSmJ4SHZ3Z0UyMGhIYTE1QWwtT2RmQS1USkJqUU5sM2RqV0xFbFMwT3IxRjJySk51X0haNTBIcVdiNldabThVbTVlNFJkNldNTFdiN3c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New narcolepsy and sleepiness findings from Axsome at SLEEP 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd2k3Q3VSZGpIRTY1S3BHUXo1eUVDVE9rcVNLVlo0RzJCV2QtYVlaa2tmSUMwUGFTeU5abXFoMU4tejl5Q2ttXzBBNjBCQjBlLXdKeWxkZWFGLVBNZFM1cFJxSjJOcDNQUmtQdThoNWFCNHBrTDdGLV82ODNyYXNmVk9ZMF94QjRqVlpQTTdTVVFfM0I1Smx1Z1RMRHZEaVVUOTk5cnk2T2oyX094QV9VWHcyNWZnc0NJWVRtaQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Herriot Tabuteau sells $11.97m in Axsome stock June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNMTZTNEZpZDJvUmF1d0lWVTZVdnY4Uk9wZnZUejZieWdtLW1HWWJHcS1XWkV0bl9MNUdvT0EzVmNnVWdZQno1WVR2SEpuR3UzWTROVDlQOFY2bG1LU3NDY1RjOF9yeE5UcUVSSGlYdktITTd6T2prUF9qOWNub0JIZEpsYURXdC1WUTVRWVVlNEx5VkZkVlpDSzFGM1NscU5PZ3BwaFhfV2ZtTnViRV9UdEpNTkFMWXRRRXBacUIxWXIwWXRsd2IwUGVwT2F4bHlZS3BLYTlrS3VnQ2hWQmN5bFllZkttQQ?oc=5", "source_name": "Billionaires.Africa", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics stock hits all-time high at 242.5 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxON2pSVXJBOFdmNWQ2SVdMWG15UGFqbnJCUzh5YTRmTEJ2YjhjQ3NpU1FyR3FWc055b2QyTUdzQ3EzR0ZQVzJmU2dJVGE3VUVPc1JaOFhhb3NCYVYzZ200T3h0U0JQQ0tMU1p2ZVF5Z1FyZ2lMMnpZbzYyMFU4X0UtY2QyWFdxdmdXS1p5NHJZbU5jVUxZaDRIRGsyb1Vlcl9rVUttWEFETGpjQ0dpbnNsbE9n?oc=5", "source_name": "Investing.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Axsome Therapeutics (AXSM) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQbkpBYTBMT2I5TDYtd2FUbXJxQ2RnN0N0RUR2NmxvWWpmWFdGWDRxd2xKbDNzY0FocEt1UXhtZFZDQjQ0bDJmYmR4VGRIaEh2VzF4YVp1UGRSOHY2c0NfTnVfdzRmZzQ2UnZCdFFDQ0RUMkdTSmtCajBLMmlxMC1OaUxEN0lMUy1QaDFCX1lFN1p3MGZGMlhqeUtza2RnUzYtVUVsRFNjV21RdlVCV0E?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics, Inc. (NASDAQ:AXSM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$270", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics Stock Gains Despite Q1 Loss Exceeding Analyst Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNTmN5OXJXNjh4RHFzZWZZam9OalB2OGxIdDdPblhpSThVMXhUd2NIYU9BRVkyYXNEQWFUT0dhamtkSnBzN1ZubU5jYTNwUHdLS21pcGhSV3VadWVqYk5lT0tpYTQ5MURHdGdyOXBBakw2YXhIblM0TGlsWGp1UVJEdWxRMmZKSUZZMi1mNEdoQkJhMFFvTjRJZWdMVlduTTZJOXp0bWlmOFZfYmZTNmc?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Q1 Loss Widening To US$64.5 Million Tests Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Will Axsome Therapeutics Stock React To Its Upcoming Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPQ3hSZHA1UHBHUmVMSS13UzY2cHZqbmdUYjE5NTh4M01Ma0xFcVpvRWtFUHpWa1QxRE1VQUpYU0l5enNWVnVpb3BxWk9va1RiMEE5VFVjM1hzYkVmdzc5QUpXUG94OFdFUmVXNWdSU1VHY0ZUZzQxQkxYeFdLa04wRGtzSVZIZWV0MEJZRXcwWURYWWhibWoyeFRqY2JxUXBZa2ZjUkxMRkFaMTE1UGxETGNTX2hwaV8wcWtJVXh4TUlTdFJv?oc=5", "source_name": "Trefis", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Axsome Therapeutics (AXSM) Still Attractively Priced After Its 72% One-Year Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQOHgtMHluM0NFTHgtUV9seF9pQ3hKaEtnRDdjS0wxNzR4SDU2Wlg2aVF1bGx2Y0ZWWS1Ma1Y4cHphQjFiMU5qdU1SdElTcGdpSF83ako5cFFRQV9KaWF4aHFTZWk2U090ZmlCR1Z2ZHQtd3FHUllXaWlxWnFpMWYyNmN4OWs0eW1BeW5mOE9pOG9neVlEenJtWEZXQTVpV2JaWFlTekRVQWZ3MGJL?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome sets May 4 earnings release, 8 a.m. call for investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQUUF3YTZKRXBSVFF1LTRJWEQ5NG9mN01Ock96M3ZpQTFTRVI2T2NEQXM2MTFMZWRwMjJZc2UtVFE0VFFCdTJkbEVYcWpLZDR0TlNLLUNJTndPdUxyLTFRLVlBR0ZydTh2eU5SZ0hjdkZqNDZMdTd6Sk5BRkpyUzVQclc0UjhzTEw3a0JvWXM4b0FwVVhnX0pBMl9ESElJLWczY3RxNjkzZzh2RTlNcGZrZ21xMmU1Rm9fYmE0OFRn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPU2M0N3UzU25NdVYxNm12TFVGZjRmVkNSRXEycUlTcnF5c3paa190SGxrVWhrOEpRZ2lqcVFJLWd6R21GWkJCbDl4SGVfOVBSbXNkdlMyckh1R3N5N1hEVldBNnpZaFFYMnlWeWJWdkNaNGpNV0Y4R3dZVnhSSnJVWTRmbHNQUkZxX01keEhBZ2FNUGszR1pjMUItTWZJTWhWeUZPY0ozc18?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Axsome Therapeutics' Recent Bull Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPTVEwc2hoc2VncjhFY05TcUx3c2s0SHJpSWoxUEJacHU1T0FoVWw4MkVYdlViaXFTeWxQeU1CRlM3Y1VVWWhVaDAtaEhGUkYtVkFNVGd1V1BaeHl0YXJHZ05GNWp3eE5nWjdlNjFWNTBFbzlLZ2U0OGNuN2dpcTVoRHJtcHNobV9QYmZ5RnFn?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-15T18:15:15+00:00", "published_display": "15 Feb 2026 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 59, "sentiment_summary": {"positive": 22, "negative": 4, "neutral": 33, "score": 59, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 74, "events": [{"event": "general", "label": "Market update", "weight": 12.45, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 7.7, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 230.0, "latest_week": "2026-07-17", "one_week_move": -1.6, "four_week_move": -8.2, "twelve_week_move": 23.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.661485, "market_dynamics_buy_signal": false, "relative_strength": 25.203143, "fair_value_gap": 100.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.0225, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.6% over one week, -8.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "MarketBeat", "count": 6}, {"label": "Stock Titan", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "Investing.com", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 14}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.6% over one week, -8.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Axsome Therapeutics (NASDAQ:AXSM) Upgraded to \"Strong-Buy\" at BMO Capital Markets"}], "updated_at": "2026-07-22T21:01:00.184945+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}